BioPharma Pharma Research
BioCity Biopharma's SC0062 Achieves Primary Endpoint in Phase 2 CKD Trial, Demonstrates Significant Proteinuria Reduction
BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reducti...
July 09, 2024 | News
Hinova Pharmaceuticals Secures FDA Fast Track Designation for HP518 in Treating AR+ Triple-Negative Breast Cancer
Hinova Pharmaceuticals a leading biopharmaceutical company dedicated to developing innovative cancer therapies, today announced that the U.S. Food an...
July 08, 2024 | News
APPIS Innovator Program 2024 Winners Announced
The APPIS Innovator Program 2024 has concluded with an impressive showcase of 49 entries from 21 countries, each addressing critical barrie...
July 04, 2024 | News
Ascentage Pharma Secures $100 Million Option Payment from Takeda for Third-Generation BCR-ABL Inhibitor
Ascentage Pharma a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies ...
July 04, 2024 | News
MEDIPAL and JCR Pharmaceuticals Announce Regulatory Review Completion for Phase I/II Trial of JR-446 in Treating Ultra-Rare Sanfilippo Syndrome Type B
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. announced the completion of the regulatory review by the Pharmaceuticals an...
July 03, 2024 | News
Sirnaomics Completes Phase I Clinical Study of STP707 for Pancreatic Cancer with Strong Safety Profile and Promising Disease Stability
Sirnaomics , a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the Group h...
July 01, 2024 | News
Huadong Medicine Announces Positive Phase I Clinical Trial Results for Oral GLP-1 Receptor Agonist HDM1002 in China
HUADONG MEDICINE, through its wholly-owned subsidiary Hangzhou Zhongmei HuaDong Pharmaceutical CO. LTD (Zhongmei HuaDong), has recently announced positive ...
June 27, 2024 | News
South Korea Approves Reimbursement for Antengene's XPOVIO®, Expanding Access to Relapsed/Refractory Multiple Myeloma Treatment
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treat...
June 27, 2024 | News
Jubilant Radiopharma Invests $50 Million to Expand PET Radiopharmaceutical Manufacturing Facilities in the U.S.
Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manuf...
June 25, 2024 | News
Merck’s SMCxPRO® Immunoassay Technology Advances Parkinson’s Disease Research Through MJFF Collaboration
SMC® immunoassay technology from Merck detects small changes in biomarker levels, indicating level of cell dysfunction New understanding of cel...
June 24, 2024 | News
Ascentage Pharma Announces Completion of Equity Investment by Takeda
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...
June 21, 2024 | News
ReviR Therapeutics and Asieris Pharmaceuticals Achieve Milestone in Cancer Treatment Collaboration
ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncolog...
June 18, 2024 | News
Ascentage Pharma Secures $1.3 Billion Deal with Takeda for Global Rights to Olverembatinib
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas. ...
June 17, 2024 | News
BeiGene and NewBridge Pharmaceuticals Conclude Partnership to Strengthen BeiGene's Direct Operations in MENA Region
BeiGene , a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with ...
June 14, 2024 | News
Most Read
- Lack of Regular Screening Fuels Rise in Late-Stage Breast Cancer in Hong Kong, New Report Reveals
- BIOCHINA 2025: Connecting Global Innovators with China's Leading Biotech Firms
- Leon Wyszkowski, President of Analytical Services, Discusses Thermo Fisher's Strategic Move: Expanding Bioanalytical Capabilities in Europe with New Sweden Lab
- The Role of Policy and Public Health Initiatives in Addressing Women's Cancer Care in Asia
- Redefining Patient Safety in the Age of Healthtech
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
Editor Picks
